A NEW tablet treatment called divarasib has shown it is very effective in treating a challenging type of bowel cancer associated with the KRAS G12C mutation.
Research published in Nature Medicine yesterday has shown "remarkable results", with 62% of people with protein KRAS G12C mutated bowel cancer achieving a positive response to treatment when given divarasib in combination with another cancer treatment called cetuximab.
Lead researcher and medical oncologist Prof Jayesh Desai explained that these results are "incredibly impressive".
"The median progression-free survival for patients in the study was just over eight months and the treatment was well tolerated with manageable side effects," Desai explained.
Learn more about the research into divarasib HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Dec 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Dec 23
